• Publications
  • Influence
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
The 2016 World Health Organization Classification of Tumors of the Central Nervous System is both a conceptual and practical advance over its 2007 predecessor and is hoped that it will facilitate clinical, experimental and epidemiological studies that will lead to improvements in the lives of patients with brain tumors. Expand
The 2007 WHO Classification of Tumours of the Central Nervous System
The fourth edition of the World Health Organization (WHO) classification of tumours of the central nervous system, published in 2007, lists several new entities, including angiocentric glioma,Expand
Malignant astrocytic glioma: genetics, biology, and paths to treatment.
The recent confluence of advances in stem cell biology, cell signaling, genome and computational science and genetic model systems have revolutionized understanding of the mechanisms underlying the genetics, biology and clinical behavior of glioblastoma. Expand
The WHO Classification of Tumors of the Nervous System
The new World Health Organization (WHO) classification of nervous system tumors, published in 2000, emerged from a 1999 international consensus conference of neuropathologists. New entities includeExpand
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
Coexpression of EGFRvIII and PTEN by glioblastoma cells is associated with responsiveness to EGFR kinase inhibitors, and effects of the molecular abnormalities in vitro are identified. Expand
WHO Classification of Tumours of the Central Nervous System. 4th Ed.
The WHO Classification of Tumours of the Central Nervous System shows clear trends in prognosis for central nervous system cancers, with prognosis improving with age and disease progression. Expand
Malignant glioma: genetics and biology of a grave matter.
Although a comprehensive view of the genetic lesions encountered in malignant gliomas has been compiled, substantive conceptual and practical barriers remain in assigning functional significance to these genetic changes and in harnessing this basic information into the development of drugs that make a difference in patient care. Expand
Pathology and genetics of tumours of the nervous system.
Tumours of the haemopoietic system Malignant lymphomas Histiocytic tumours, Familial tumour syndromes, and metastatic tumours ofThe CNS. Expand
Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1.
It is shown that the activation of phosphatidylinositol 3 (PI3) kinase by extracellular growth factors induces phosphorylation, nuclear export, and transcriptional inactivation of FKHR1, a member of the FK HR subclass of the forkhead family of transcription factors. Expand
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.
Results suggest that a tumor-specific alteration of the EGFR plays a significant role in tumor progression perhaps by influencing interactions of tumor cells with their microenvironment in ways not easily assayed in vitro. Expand